Tech Company Inital Public Offerings
Immix Biopharma IPO
Immix Biopharma was acquired by . Shares became public on 12/16/2021.
Transaction Overview
Company Name
Announced On
12/16/2021
Transaction Type
IPO
Amount
$21,000,000
Proceeds Purpose
We intend to use approximately $9.8 million of the net proceeds from this offering to fund our planned IMX-110 Phase 2a STS clinical trial and our IMX-110 + tislelizumab Phase 1b combination trial and approximately $6.7 million of the net proceeds from this offering for IND-enabling studies for IMX-111 (colorectal cancer) and IMX-120 (inflammatory bowel disease). The balance of the net proceeds is expected to be used for general working capital purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
11150 W. Olympic Blvd.
Los Angeles, CA 90064
USA
Los Angeles, CA 90064
USA
Phone
Website
Email Address
Overview
Immix Biopharma, Inc. is a privately held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ilya Rachman
Co-Founder
Sean Senn
Co-Founder
Vladimir Torchilin
Browse more venture capital transactions:
Prev: 12/16/2021: Cequence Security venture capital transaction
Next: 12/16/2021: Runway venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs